Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple Myeloma
This is a Phase 1, multicenter, open-label study o evaluate the safety and efficacy of CART-BCMA in subjects with relapsed/refractory multiple myeloma.
Multiple Myeloma
DRUG: CART-BCMA
The incidence of all adverse events and serious adverse events, The safety and tolerability of CART-BCMA were evaluated according to the the incidence of all adverse events and serious adverse events, Day 1 through Month 24|BCMA-CART Maximum Tolerable Dose (MTD) and/or Recommends Dose (RD), BCMA-CART Maximum Tolerable Dose (MTD) and/or Recommends Dose (RD), Day 1 through Month 24
The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CART-BCMA to establish a recommended dose (RD); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CART-BCMA at the RD.